Payment overview · 2025
General Payments
$210.85
10 reported records · 6 companies
Healthcare provider profile · identity verified
Ohad Sheffy, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · VIRGINIA BEACH, VA · NPI 1295087005
Verified facts
What the public records show
CMS Open Payments records show Ohad Sheffy, M.D. received $210.85 in general payments during 2025 across 10 reported records.
ABBVIE INC. accounted for 28.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 211 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $59.54 | 28.2% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $47.98 | 22.8% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $44.09 | 20.9% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $31.92 | 15.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.78 | 6.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.54 | 6.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $210.85 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $59.54 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $59.54 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $47.98 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $44.09 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $31.92 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.43 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.78 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $13.78 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.54 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
211 | 36 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 654 | 202 |
| Amlodipine Besylate | Amlodipine Besylate | 473 | 167 |
| Losartan Potassium | Losartan Potassium | 270 | 96 |
| Furosemide | Furosemide | 240 | 79 |
| Eliquis | Apixaban | 211 | 36 |
| Carvedilol | Carvedilol | 206 | 62 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 196 | 108 |
| Metoprolol Tartrate | Metoprolol Tartrate | 186 | 77 |
| Omeprazole | Omeprazole | 185 | 79 |
| Tamsulosin Hcl | Tamsulosin Hcl | 175 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 169 | 85 |
| Levothyroxine Sodium | Levothyroxine Sodium | 163 | 59 |
| Potassium Chloride | Potassium Chloride | 139 | 38 |
| Lisinopril | Lisinopril | 134 | 58 |
| Gabapentin | Gabapentin | 124 | 63 |
| Mirtazapine | Mirtazapine | 124 | 44 |
| Quetiapine Fumarate | Quetiapine Fumarate | 118 | 31 |
| Sertraline Hcl | Sertraline Hcl | 116 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 110 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 110 | 50 |
| Clopidogrel | Clopidogrel Bisulfate | 99 | 34 |
| Trazodone Hcl | Trazodone Hcl | 97 | 35 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 95 | 14 |
| Pantoprazole Sodium | Pantoprazole Sodium | 95 | 29 |
| Montelukast Sodium | Montelukast Sodium | 93 | 43 |
| Duloxetine Hcl | Duloxetine Hcl | 91 | 25 |
| Spironolactone | Spironolactone | 87 | 26 |
| Metformin Hcl | Metformin Hcl | 86 | 40 |
| Bumetanide | Bumetanide | 82 | 36 |
| Prednisone | Prednisone | 80 | 53 |
| Donepezil Hcl | Donepezil Hcl | 77 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 77 | 29 |
| Levetiracetam | Levetiracetam | 76 | 19 |
| Simvastatin | Simvastatin | 74 | 23 |
| Warfarin Sodium | Warfarin Sodium | 68 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 64 | 33 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 63 | 19 |
| Allopurinol | Allopurinol | 60 | 24 |
| Entresto | Sacubitril/Valsartan | 58 | suppressed |
| Finasteride | Finasteride | 57 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 54 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 54 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 54 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 52 | 23 |
| Alendronate Sodium | Alendronate Sodium | 49 | 21 |
| Glipizide | Glipizide | 49 | 31 |
| Baclofen | Baclofen | 48 | 14 |
| Risperidone | Risperidone | 46 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 45 | 11 |
| Memantine Hcl | Memantine Hcl | 45 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | 12 |
| Latanoprost | Latanoprost | 42 | suppressed |
| Tranexamic Acid | Tranexamic Acid | 41 | suppressed |
| Jardiance | Empagliflozin | 40 | suppressed |
| Ozempic | Semaglutide | 40 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 39 | 23 |
| Divalproex Sodium | Divalproex Sodium | 39 | suppressed |
| Nifedipine Er | Nifedipine | 39 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 37 | 21 |
| Xarelto | Rivaroxaban | 37 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 35 | 20 |
| Meloxicam | Meloxicam | 35 | 21 |
| Buspirone Hcl | Buspirone Hcl | 34 | suppressed |
| Cephalexin | Cephalexin | 34 | 16 |
| Januvia | Sitagliptin Phosphate | 34 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | 22 |
| Famotidine | Famotidine | 32 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 30 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 25 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | 16 |
| Fluconazole | Fluconazole | 27 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | 14 |
| Oxcarbazepine | Oxcarbazepine | 27 | suppressed |
| Atenolol | Atenolol | 25 | 14 |
| Glimepiride | Glimepiride | 25 | 12 |
| Lorazepam | Lorazepam | 25 | 23 |
| Brilinta | Ticagrelor | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | 12 |
| Tramadol Hcl | Tramadol Hcl | 24 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Ibuprofen | Ibuprofen | 22 | 17 |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Torsemide | Torsemide | 22 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 21 | 20 |
| Nystatin | Nystatin | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 19 |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Ezetimibe | Ezetimibe | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | 11 |
| Sulfasalazine | Sulfasalazine | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 11 |
| Ceftriaxone | Ceftriaxone Sodium | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | 11 |
| Alprazolam | Alprazolam | 15 | suppressed |
| Calcium Acetate | Calcium Acetate | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 14 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 15 | 14 |
| Febuxostat | Febuxostat | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 14 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 14 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 14 | 14 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Letrozole | Letrozole | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | 11 |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Humalog Junior Kwikpen | Insulin Lispro | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $210.85 · 10 records | ABBVIE INC. | Cologuard Collection Kit, FREESTYLE LIBRE 3, MOUNJARO, NURTEC ODT, OTEZLA, PAXLOVID, QULIPTA, REPATHA, UBRELVY, ZEPBOUND | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error